Charles Cherington - 10 Feb 2026 Form 4 Insider Report for Ernexa Therapeutics Inc. (ERNA)

Reporting relationship: 10%+ Owner
Issuer ticker: ERNA
Reported as of: 10 Feb 2026
Net transaction value: +$2,000,000
SEC form: 4
Accepted by SEC: 17 Feb 2026, 21:14:34 UTC
Prior SEC filing: 11 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Charles Cherington

Key filing fact

Charles Cherington filed Form 4 for Ernexa Therapeutics Inc. (ERNA) on 17 Feb 2026.

Key facts

This page summarizes Charles Cherington's Form 4 filing for Ernexa Therapeutics Inc. (ERNA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2026, 21:14.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: +$2,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001448698 Primary reporting owner

Cherington Charles

Relationship: 10%+ Owner
Address: 200 BERKLEY STREET, 26TH FLOOR, BOSTON
Signature: /s/ Charles Cherington
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ERNA transaction

Common Stock

Purchase

Transaction value: $2,000,000
Shares: +4,000,000
Change %: +144%
Price: $0.5000
Shares after: 6,779,440
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA transaction Derivative

Warrants to Purchase Common Stock

Purchase

Transaction value
Shares: +4,000,000
Change %
Price
Shares after: 4,000,000
Date: 10 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,000,000
Exercise price: $0.6800
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026.

Footnote F2

The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50.

Footnote F3

The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.

SEC remarks

This form is being filed late due to delays encountered during the Reporting Person's initial enrollment and account authorization within the SEC's EDGAR Next System.